PEDIATRICS Vol. 50 No. 1 July 1972, pp. 127-130
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linde, L. M.
Right arrow Articles by Awa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linde, L. M.
Right arrow Articles by Awa, S.

PRESENT STATUS AND TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

Leonard M. Linde M.D.1, Searle W. Turner M.D.1, and Shoichi Awa M.D.1

1 Department of Pediatrics, UCLA School of Medicine, Los Angeles, California

The therapeutic agents that have been described will successfully convert close to 100% of all episodes of PST in children. Digoxin is the most frequently used agent for treatment of acute PST and is highly effective and safe. Recently, cardioversion and beta-adrenergic blockade are being employed more frequently, both with specific indications. Newer electrical means and new agents such as Verapamil are effective but the former are not yet widely used and the latter not yet authorized for use in the United States. Prophylaxis of recurrent episodes is usually successful with digoxin, with the addition or substitution of propranolol in certain conditions.